Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Blood ; 144(10): 1083-1092, 2024 Sep 05.
Article in English | MEDLINE | ID: mdl-38820500

ABSTRACT

ABSTRACT: Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus, the open-label, randomized phase 2 ECOG-ACRIN Cancer Research Group E1411 trial was designed to test 2 questions: (1) does addition of bortezomib to BR induction (BVR) and/or (2) addition of lenalidomide to rituximab (LR) maintenance improve progression-free survival (PFS) in patients with treatment-naïve MCL? From 2012 to 2016, 373 previously untreated patients, 87% aged ≥60 years, were enrolled in this trial. At a median follow-up of 7.5 years, there is no difference in the median PFS of BR compared with BVR (5.5 vs 6.4 years; hazard ratio [HR], 0.90; 90% confidence interval [CI], 0.70-1.16). There were no unexpected additional toxicities with BVR treatment compared with BR, with no impact on total dose/duration of treatment received. Independent of the induction treatment, addition of lenalidomide did not significantly improve PFS, with median PFS in R vs LR (5.9 vs 7.2 years; HR, 0.84; 90% CI, 0.62-1.15). Most patients completed the planned 24 cycles of LR at the scheduled dose. In summary, adding bortezomib to BR induction does not prolong PFS in treatment-naïve MCL, and LR maintenance was not associated with longer PFS compared with R alone after BR. Nonetheless, the >5-year median PFS outcomes in this prospective cooperative group trial indicate the efficacy of BR followed by R maintenance as highly effective initial therapy for older patients with MCL. This trial was registered at www.clinicaltrials.gov as #NCT01415752.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Bendamustine Hydrochloride , Bortezomib , Lenalidomide , Lymphoma, Mantle-Cell , Maintenance Chemotherapy , Rituximab , Humans , Rituximab/administration & dosage , Rituximab/therapeutic use , Bendamustine Hydrochloride/administration & dosage , Bendamustine Hydrochloride/therapeutic use , Bortezomib/administration & dosage , Bortezomib/therapeutic use , Lenalidomide/administration & dosage , Lenalidomide/therapeutic use , Female , Male , Middle Aged , Aged , Lymphoma, Mantle-Cell/drug therapy , Lymphoma, Mantle-Cell/mortality , Lymphoma, Mantle-Cell/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Aged, 80 and over , Adult , Induction Chemotherapy , Progression-Free Survival
2.
Gen Dent ; 57(6): 637-43, 2009.
Article in English | MEDLINE | ID: mdl-19906616

ABSTRACT

A resin acrylic and plaster solder index technique is a simple, accurate, secure, and cost-effective way to intraorally realign an ill-fitting fixed partial denture framework. Once the fixed partial denture framework is sectioned and segments are found to fit, an intraoral index preserves the correct relationship among segments and holds castings together securely enough to avoid separating until they can be embedded in solder investment and soldered in the dental laboratory. This technique is described here, together with a literature review and a discussion of the technique's advantages relative to other indexing techniques and materials.


Subject(s)
Denture Repair/methods , Denture, Partial, Fixed , Acrylic Resins , Calcium Sulfate , Dental Soldering , Humans , Prosthesis Fitting , Waxes
SELECTION OF CITATIONS
SEARCH DETAIL